Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5a-dihydrotestosterone (DHT), promoting signalling by the androgen receptor and the development of castration-resistant prostate cancer 1-3 . Essential for resistance, DHT synthesis from adrenal precursor steroids or possibly from de novo synthesis from cholesterol commonly requires enzymatic reactions by 3b-hydroxysteroid dehydrogenase (3bHSD), steroid-5a-reductase (SRD5A) and 17b-hydroxysteroid dehydrogenase (17bHSD) isoenzymes 4,5 . Abiraterone, a steroidal 17a-hydroxylase/17,20-lyase (CYP17A1) inhibitor, blocks this synthetic process and prolongs survival 6,7 . We hypothesized that abiraterone is converted by an enzyme to the more active D 4 -abiraterone (D4A), which blocks multiple steroidogenic enzymes and antagonizes the androgen receptor, providing an additional explanation for abiraterone's clinical activity. Here we show that abiraterone is converted to D4A in mice and patients with prostate cancer. D4A inhibits CYP17A1, 3bHSD and SRD5A, which are required for DHT synthesis. Furthermore, competitive androgen receptor antagonism by D4A is comparable to the potent antagonist enzalutamide. D4A also has more potent anti-tumour activity against xenograft tumours than abiraterone. Our findings suggest an additional explanation-conversion to a more active agent-for abiraterone's survival extension. We propose that direct treatment with D4A would be more clinically effective than abiraterone treatment.
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5a-dihydrotestosterone (DHT), promoting signalling by the androgen receptor and the development of castration-resistant prostate cancer [1] [2] [3] . Essential for resistance, DHT synthesis from adrenal precursor steroids or possibly from de novo synthesis from cholesterol commonly requires enzymatic reactions by 3b-hydroxysteroid dehydrogenase (3bHSD), steroid-5a-reductase (SRD5A) and 17b-hydroxysteroid dehydrogenase (17bHSD) isoenzymes 4, 5 . Abiraterone, a steroidal 17a-hydroxylase/17,20-lyase (CYP17A1) inhibitor, blocks this synthetic process and prolongs survival 6, 7 . We hypothesized that abiraterone is converted by an enzyme to the more active D 4 -abiraterone (D4A), which blocks multiple steroidogenic enzymes and antagonizes the androgen receptor, providing an additional explanation for abiraterone's clinical activity. Here we show that abiraterone is converted to D4A in mice and patients with prostate cancer. D4A inhibits CYP17A1, 3bHSD and SRD5A, which are required for DHT synthesis. Furthermore, competitive androgen receptor antagonism by D4A is comparable to the potent antagonist enzalutamide. D4A also has more potent anti-tumour activity against xenograft tumours than abiraterone. Our findings suggest an additional explanation-conversion to a more active agent-for abiraterone's survival extension. We propose that direct treatment with D4A would be more clinically effective than abiraterone treatment.
The central role and critical requirement for androgen metabolism and androgen receptor (AR) in castration-resistant prostate cancer (CRPC) are demonstrated by the clinical benefit and overall survival benefit conferred by abiraterone (Abi) 6, 7 , which blocks CYP17A1, an enzyme required for androgen synthesis, and enzalutamide, which potently and competitively blocks the AR 8, 9 . Abi (administered in its acetate form for bioavailability) is a steroidal compound and is therefore potentially subject to conversion by steroid-metabolizing enzymes. We hypothesized that the D 5 , 3b-hydroxyl-structure of Abi, which is also present in the natural steroid substrates dehydroepiandrosterone (DHEA) and D 5 -androstenediol (A5diol), makes it susceptible to one enzyme conversion by 3bHSD isoenzymes to its D 4 , 3-keto congener (D 4 -abiraterone or D4A). This, in turn, would make the steroid A and B rings identical to testosterone, enabling inhibitory interactions with AR and additional steroidogenic enzymes, including SRD5A, which are required for DHT synthesis (Fig. 1a ). Such a conversion in peripheral tissues would allow D4A to engage with multiple targets to potentiate its effects on the androgen pathway, providing an alternative explanation for the clinical efficacy of Abi therapy and thus the possibility that direct treatment might be more efficacious.
We found that D4A is detectable in the sera of mice administered Abi acetate ( Fig. 1b ), as well as in sera from patients with CRPC who were undergoing treatment with Abi acetate (Fig. 1c, d and Extended Data Fig. 1 ). In the LAPC4 prostate cancer cell line, which usually has low 3bHSD activity 3 , conversion of Abi to D4A is detectable only if 3bHSD is overexpressed ( Fig. 1e and Extended Data Fig. 2a, b ). Other tissues such as the mouse adrenal (but not mouse prostate) that have robust endogenous 3bHSD enzymatic activity also convert Abi to D4A (Extended Data Fig. 2c ). These results suggest that D4A is a major metabolite of Abi, requires 3bHSD for conversion and may confer effects on the tumour that are indirectly due to Abi.
D4A may impinge on multiple steps in the androgen pathway, including CYP17A1, 3bHSD, SRD5A and direct interaction with AR ( Fig. 2a ). Although augmented Abi drug exposure may block 3bHSD, Fig. 3a ) and high-performance liquid chromatography (HPLC; Fig. 2b and Extended Data Fig. 3b ). D4A inhibits both human isoenzymes, 3bHSD1 and 3bHSD2, with mixed inhibition kinetics ( Fig. 2c ). CYP17A1 inhibition is the major direct mechanism of action for Abi 11 (Fig. 2d ). The D 4 , 3-keto-structure of D4A is identical to physiological SRD5A substrates, such as testosterone and AD ( Fig. 1a ) 13 . To determine the effect of D4A on endogenously expressed SRD5A, LAPC4 cells, which exhibit robust SRD5A enzymatic activity 13 , were treated with D4A, Abi or enzalutamide and cultured in the presence of [ 3 H]AD (the preferred natural substrate of SRD5A1 (ref. 13) ). D4A (10 mM) nearly completely blocked conversion from AD to 5a-androstanedione and other 5a-reduced androgens, whereas Abi and enzalutamide had no detectable effect even at a concentration of 100 mM ( Fig. 2e ). Abi has been reported to have modest affinity for AR, particularly in the presence of mutations in the ligand-binding domain 14 . Conversion Arrows denote AD percentage for 0.1 mM D4A and 1 mM Abi treatment groups. c, Lineweaver-Burk plots of pregnenolone metabolism and D4A inhibition of human 3bHSD1 and 3bHSD2 activity. D4A shows mixed competitivenon-competitive inhibition for 3bHSD1 and non-competitive inhibition for 3bHSD2. d, CYP17A1 inhibition with D4A is comparable to Abi. HEK 293 cells stably expressing CYP17A1 were treated with 0.1, 1 or 10 nM D4A, or Abi, together with [ 3 H]pregnenolone for 3 and 6 h. Pregnenolone and DHEA were separated and quantified by HPLC. e, D4A but not Abi or enzalutamide inhibits 5a-reductase activity. LAPC4 cells were treated with [ 3 H]AD and the indicated drug concentrations. Steroids were quantified by HPLC. Arrows denote 5areduced androgen percentage for 10 mM D4A and 100 mM Abi treatment groups. All experiments were performed with biological replicates (n 5 3) and repeated independently three times. All results are shown as mean 6 s.d.
of Abi by 3bHSD to D4A would provide a 3-keto structure, which is shared by both testosterone and DHT, steroids with the highest affinity for AR ( Fig. 1a ). To determine how conversion from Abi to the 3-keto structure of D4A affects drug affinity for AR, we performed a competition assay. The affinity of D4A for mutant (expressed in LNCaP, half-maximum inhibitory concentration (IC 50 ) 5 5.3 nM) and wildtype (expressed in LAPC4, IC 50 5 7.9 nM) AR is greater than that of Abi (IC 50 5 418 and .500 nM, respectively), comparable to or slightly greater than that of enzalutamide (IC 50 5 24 and 23 nM, respectively; Fig. 3a, b) , and clearly greater than bicalutamide, which was the most potent competitive non-steroidal AR antagonist before the introduction of enzalutamide (Extended Data Fig. 4a, b ). The affinity of D4A for the AR ligand-binding domain translates to inhibition of DHTinduced AR chromatin occupancy on the PSA, TMPRSS2 and FKBP5 regulatory elements on chromatin, which is superior to Abi (Extended Data Fig. 4c ) and somewhat lower than enzalutamide (Fig. 3c ). The incongruity between AR affinity and effects on chromatin occupancy for D4A and enzalutamide is consistent with combined AR antagonism and chromatin binding in an inactive complex, as previously reported for some AR antagonists 15 .
We next examined the cumulative results of the effects of D4A on androgen-responsive gene expression. Compared with Abi, D4A clearly better suppresses PSA, TMPRSS2 and FKBP5 expression induced by DHT, DHEA and R1881 in LNCAP, LAPC4 and C4-2 cell lines ( Fig. 3d and Extended Data Fig. 5a , c). D4A inhibits AR target gene expression in a dose-dependent manner (Extended Data Fig. 5b, d ).
Comparisons of D4A with enzalutamide on DHT-induced endogenous PSA expression demonstrate that D4A is equivalent to enzalutamide against mutant and wild-type AR (Fig. 3e , f and Extended Data Fig. 5c,  d ). Downstream of androgen-responsive gene expression, effects of D4A and enzalutamide on DHT-stimulated cell growth are equivalent ( Fig. 3g ), both of which are more potent than Abi.
To determine whether the observed effects of D4A on inhibition of steroid synthesis demonstrated in tissue culture also occur in tumours, effects in two prostate cancer xenograft models with robust 3bHSD enzymatic activity 3 were assessed. Subcutaneous mouse xenograft tumours of VCaP and LNCaP cells, which both harbour a mutant gene encoding a missense in 3bHSD1 that effectively increases enzyme activity 3 , were grown in male NSG mice. Fresh tumours were harvested, minced and incubated with [ 3 H]DHEA plus Abi or D4A (0.1-10 mM). Similar to effects shown in Fig. 2 , D4A is tenfold more potent than Abi in blocking conversion from DHEA by 3bHSD to AD in LNCaP ( Fig. 4a ) and VCaP xenografts ( Fig. 4b ). For example, 0.1 mM D4A is equivalent to 1 mM Abi for blocking AD accumulation at 48 h in both LNCaP and VCaP xenografts. To test whether the combined effects of D4A on inhibition of steroid synthesis and direct blockade of AR lead to augmented anti-tumour activity compared with Abi, VCaP xenografts were grown subcutaneously in orchiectomized mice with DHEA pellet implantation (to mimic human adrenal physiology; Fig. 4c ). Time from initiation of treatment with D4A, Abi acetate or vehicle to tumour progression (.20% increase in tumour volume) was assessed by generating Kaplan-Meier survival curves 
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and comparing treatment groups with the log-rank test. Progression was significantly delayed in the D4A group compared with the Abi acetate group (P 5 0.011). Fold-change in tumour volume is shown for each treatment group in Extended Data Fig. 6 . We also compared xenograft growth using the same method with the C4-2 cell line model. D4A treatment increased progression-free survival compared with Abi acetate and enzalutamide (Fig. 4d ). In serum collected from D4Atreated mice at the end of the xenograft study there was no detectable increase in deoxycorticosterone, which is the mineralocorticoid that is most highly elevated in patients treated with Abi acetate, causing hypertension and hyperkalaemia (Extended Data Fig. 7 ) 6, 16 . Figure 4e depicts the multiple points in the androgen pathway at which conversion of Abi by 3bHSD to D4A in patients impinges on AR signalling and prostate cancer progression, and the relative potencies of D4A, Abi and enzalutamide. The next-generation hormonal therapies, Abi and enzalutamide, each have a single predominant target (CYP17A1 and AR, respectively). These drugs have clinically validated that androgen synthesis and AR stimulation are both essential components required to spur the development and progression of CRPC. After oral administration, Abi acetate is hydrolysed and thereby converted to Abi, which is thought to be the major active agent by way of blocking CYP17A1. The major recognized metabolites of Abi result from hepatic CYP3A4 and SULT2A1 processing, forming the N-oxide of Abi and Abi sulfate, respectively. Neither of these modifications affects the D 5 , 3bhydroxyl-structure of the steroid backbone. In contrast, conversion to D4A modifies the steroidal structure to one that more robustly engages with AR, SRD5A and 3bHSD, thereby blocking androgen signalling at all these steps, while retaining CYP17A1 inhibition. The clinical significance of conversion of Abi to D4A and effects on individual components of the androgen pathway in patients must be viewed in light of pharmacokinetic studies that show a maximum serum concentration (C max ) of approximately 1 mM and also wide inter-patient variability 16 . Furthermore, our findings suggest that D4A also has much more potent anti-tumour activity against CRPC when directly compared with Abi.
The potential clinical utility of treating patients with CRPC directly with D4A is dependent on the underlying mechanisms of resistance to Abi, which have not been fully elucidated, and the clinical settings in which the benefit from Abi is exhausted. The evidence suggests that sustained AR signalling characterizes at least a subset of Abi resistance cases. For example, increased AR copy number in CRPC is associated with absence of clinical response to Abi 17 , and increased AR protein expression appears to occur upon the development of acquired clinical resistance to Abi 18 . Although Abi is a potent CYP17A1 inhibitor, studies of urinary steroid metabolites in patients demonstrate that androgen synthesis inhibition is incomplete, raising the possibility of sustained steroidogenesis as a mechanism of resistance 5, 19 . Clinically, the combination of CYP17A1 inhibition and a potent AR antagonist appears to confer more potent androgen signalling inhibition in patients with CRPC 20 .
Circulating concentrations of D4A in patients treated with Abi acetate appear to be quite variable. In contrast to hepatic Abi metabolites, it is probable that conversion of Abi to D4A in peripheral tissues leads to D4A concentrations that are higher in peripheral tissues (such as CRPC) than are present in serum. The effects of D4A on androgen signalling in CRPC, in particular distal steps in DHT synthesis and activity as an AR antagonist, may therefore be underestimated on the basis of serum concentrations alone. Nonetheless, D4A levels in peripheral tissues and the precise contribution of D4A to the clinical activity of Abi have yet to be determined.
Finally, our results raise the possibility that there may be a previously unappreciated class effect of steroidal versus non-steroidal CYP17A1 inhibitors. In contrast to Abi acetate, TAK-700, a nonsteroidal CYP17A1 inhibitor, failed to prolong survival in metastatic CRPC 21 . It is possible that the absence of active downstream steroidal metabolites may have contributed to these findings. This issue should be considered as other steroidal and non-steroidal CYP17A1 inhibitors undergo further clinical investigation. DHEA and AD were separated and quantified by HPLC. Experiments were performed with biological replicates (n 5 3 xenograft tissues) and results are shown as mean 6 s.d. Arrows denote AD percentage for 0.1 mM D4A and 1 mM Abi treatment groups. c, D4A is more potent than Abi for blocking VCaP xenograft progression. Time to xenograft progression (.20% increase in tumour volume) is shown for vehicle (control; n 5 9 mice), Abi acetate (AA; n 5 10) and D4A (n 5 10) treatment groups. All three treatment groups differ significantly from one another: control versus AA, P 5 0.02; control versus D4A, P , 0.001; AA versus D4A, P 5 0.01. d, D4A (n 5 10) is more potent than AA (n 5 10) and Enz (n 5 11) for blocking C4-2 xenograft progression: control versus D4A, P , 0.001; AA versus D4A, P 5 0.01; Enz versus D4A, P 5 0.02. e, Schematic of D4A activities and IC 50 in the androgen pathway and comparisons with Abi and Enz.
In conclusion, we have identified a novel Abi metabolite that is present in patients with CRPC treated with Abi acetate and has more potent anti-tumour activity than the parent drug. Conversion to D4A may be responsible for some of the clinical activity observed with the use of Abi. We suggest that treatment with D4A is likely to result in a greater clinical benefit than Abi.
METHODS
No statistical methods were used to predetermine sample size. Cell lines. LNCaP and VCaP cells were purchased from the American Type Culture Collection and maintained in RPMI-1640 with 10% FBS. LAPC4 cells were provided by C. Sawyers and grown in Iscove's Modified Dulbecco's Medium with 10% FBS. C4-2 cells were provided by L. Chung and maintained in RPMI-1640 with 10% FBS. All experiments using LNCaP and VCaP were performed in plates coated with poly-DL-ornithine (Sigma-Aldrich). A 293-cell line stably expressing human CYP17A1 was generated by transfection with (pcDNA3)-CYP17 (a gift from W. Miller) and selection with G418 as described 22 . Cell lines were authenticated by DDC Medical and determined to be negative for mycoplasma with primers 59-ACACCATGGGAGCTGGTAAT-39 and 59-GTTCAT CGACTTTCAGACCCAAGGCAT-39. Chemicals. Abi acetate was purchased from Medkoo Biosciences. Abi and D4A were synthesized as described previously 10 . Enzalutamide was obtained from Medivation. Steroid metabolism. Cell line metabolism. Cells were seeded and incubated in 12well plates with 0.2 million cells per well for ,24 h and then incubated with a mixture of radioactive ( 3 H-labelled) and non-radioactive androgens (final concentration, 100 nM; ,1,000,000 counts per minute (c.p.m.) per well; PerkinElmer) at 37 uC. Aliquots of medium were collected at the indicated times. Collected medium was treated with 1,000 units of b-glucuronidase (Helix pomatia; Sigma-Aldrich) at 65 uC for 2 h, extracted with 860 ml ethyl acetate:isooctane (1:1), and concentrated under nitrogen gas.
Xenograft metabolism. Ten million LNCaP or VCaP cells were injected subcutaneously with Matrigel into surgically orchiectomized NSG mice that were implanted with 5 mg 90-day sustained-release DHEA pellets (Innovative Research of America). Xenografts were harvested when they reached 1,000 mm 3 , minced, and cultured in DMEM with 10% FBS at 37 uC with a mixture of radioactive ( 3 H-labelled) and non-radioactive androgens, or Abi, when they reached 1,000 mm 3 . Each xenograft was analysed in triplicate in at least three independent experiments. Aliquots of medium were collected at the indicated times. Collected medium was treated with 1,000 units of b-glucuronidase at 65 uC for 2 h, extracted with 860 ml ethyl acetate:isooctane (1:1) and concentrated under nitrogen gas.
HPLC analysis was performed on a Waters 717 Plus HPLC or an Agilent 1260 HPLC. Dried samples were reconstituted in 50% methanol and injected into the HPLC. Steroids and drug metabolites were separated on a Kinetex 100 mm 3 2.1 mm, 2.6 mm particle size C 18 reverse-phase column (Phenomenex) using a methanol/water gradient at 30 uC. The column effluent was analysed using a dualwavelength ultraviolet-visible detector set at 254 nm or b-RAM model 3 in-line radioactivity detector (IN/US Systems) using Liquiscint scintillation cocktail (National Diagnostics). Alternatively, dried samples were applied to plasticbacked silica gel plates and separated by TLC using a mobile phase of 3:1 chloroform:ethyl acetate, followed by exposure of the plates to a phosphorimager screen and quantitated with a Storm model 860 phosphorimager (Applied Biosystems). All HPLC and TLC studies were conducted in triplicate and repeated at least three times in independent experiments. Results are shown as mean 6 s.d. Gene expression. Cells were starved with phenol-red-free and serum-free medium for at least 48 h and treated with the indicated drugs and/or androgens. RNA was extracted with a GenElute Mammalian Total RNA miniprep kit (Sigma-Aldrich). cDNA was synthesized from 1 mg RNA in a reverse transcription reaction using the iScript cDNA Synthesis Kit (Bio-Rad). qPCR analysis was conducted in triplicate with primers for PSA, TMPRSS2, FKBP5 and RPLPO described previously 3 , with an ABI 7500 Real-Time PCR machine (Applied Biosystems) using iTaq Fast SYBR Green Supermix with ROX (Bio-Rad) in 96-well plates at a final reaction volume of 20 ml. Accurate quantitation of each messenger RNA was achieved by normalizing the sample values to RPLPO and to vehicle-treated cells. ChIP assay. LNCaP cells were serum-starved for at least 48 h and treated with indicated drugs and DHT for 3 h. A ChIP assay was performed with an anti-AR antibody (Santa Cruz, sc-816) as described previously 23 . All of the precipitated DNA samples were quantified by qPCR and normalized to input DNA. All ChIP experiments were performed at least three times. Primers used for ChIP experiments were from experiments previously described 24 . Primer sequences were as follows: PSA: 59-TGGGACAACTTGCAAACCTG-39 and 59-CCAGAGTAGG TCTGTTTTCAATCCA-39; FKBP5: 59-CCCCCTATTTTAATCGGAGTAC-39 and 59-TTTTGAAGAGCACAGAACACCT-39; TMPRSS2: 59-TGGTCCTGG ATGATAAAAAAAGTTT-39 and 59-GACATACGCCCCACAACAGA-39. Mouse xenograft studies. Male NSG mice, 6-8 weeks of age, were obtained from the Cleveland Clinic Biological Resources Unit facility. All mouse studies were conducted under a protocol approved by the Cleveland Clinic Institutional Animal Care and Use Committee. Sample size was determined on the basis of our prior studies of steroidogenesis inhibition in xenograft models of CRPC 3, 13 . Criteria for progression were determined on the basis of similar criteria used for clinical progression. Mice were surgically orchiectomized and implanted with a 5 mg 90-day sustained-release DHEA pellet (Innovative Research of America) to mimic CRPC in the context of human adrenal physiology. Two days later, 10 7 VCaP or C4-2 cells were injected subcutaneously with matrigel. Once tumours reached 300 mm 3 (length 3 width 3 height 3 0.52), mice were arbitrarily (but not strictly randomized) assigned to vehicle (n 5 9 or 10 mice for VCaP and C4-2 respectively), Abi acetate (n 5 10 mice for both cell lines), D4A (n 5 10 mice for both cell lines) or enzalutamide (n 5 11 for C4-2) treatment groups. Abi acetate and D4A (0.5 mmol per kg per day in 0.1 ml 5% benzyl alcohol and 95% safflower oil solution) were administered via 5 ml per kg intraperitoneal injection every day for up to 15 days. Control groups were administered 0.1 ml 5% benzyl alcohol and 95% safflower oil solution via intraperitoneal injection every day. Mice in the enzalutamide group were fed with enzalutamide in chow every day (10 mg per kg per day) 25 . Treatment was not blinded to the investigator. Tumour volume was measured daily, and time to increase in tumour volume by 20% was determined. Mice were killed at treatment day 15 or when the tumour size was twofold greater than baseline. The significance of the difference between treatment groups was assessed by Kaplan-Meier survival analysis using a log-rank test in SigmaStat 3.5. A two-tailed Student's t-test was used to determine significance in Extended Data Fig. 6 . Enzyme assays. To test D4A as an inhibitor of 3bHSD, enzyme assays were performed as described previously 10 . Briefly, incubations were prepared with recombinant human 3bHSD1 or 3bHSD2 (in yeast microsomes, 45 or 2.5 mg protein per incubation, respectively), [ 3 H]pregnenolone (100,000 c.p.m., 1-20 mM), and D4A (5-20 mM) or ethanol vehicle in 0.5 ml of potassium phosphate buffer (pH 7.4). After a pre-incubation at 37 uC for 1-3 min, NAD 1 (1 mM) was added, and the incubation was conducted at 37 uC for 20 min. The reaction was stopped by addition of 1 ml ethyl acetate:isooctane (1:1), and the steroids were then extracted into the organic phase and dried. The steroids in the dried extracts were resolved by HPLC and quantitated by in-line scintillation counting. AR competition assay. Cells were cultured in serum-free medium for 48 h and then treated with [ 3 H]R1881 and the indicated concentrations of D4A, Abi, enzalutamide, R1881 or bicalutamide for 30 min. Cells were washed with 13 PBS four times and 0.9% NaCl solution twice before lysis with RIPA buffer. Intracellular radioactivity was measured with a Beckman Coulter LS60001C liquid scintillation counter and normalized to the protein concentration as detected with a Wallac Victor2 1420 Multilabel counter (PerkinElmer). Cell proliferation assay. LNCaP cells (0.1 million cells per millilitre) were seeded in 96-well plates and cultured in phenol-red-free RPMI-1640 mediums plus 10% charcoal stripped FBS with androgens and/or drugs. Medium was changed every other day. After 2, 4 or 6 days, cells were collected and lysed after treatment. Growth was then determined on the basis of DNA content as detected by Hoechst stain and a Wallac Victor2 1420 Multilabel counter (PerkinElmer). A two-tailed Student's t-test was used to determine significance. Mass spectrometry. Patient serum collection and drug extraction. Twelve patients with CRPC undergoing treatment with Abi acetate were consented under an Institutional Review Board-approved protocol (case 7813). Blood was collected using Vacutainer Plus serum blood collection tubes (BD367814, Becton Dickinson). Blood was collected between 2 and 14 h after the 1,000 mg daily dose of Abi acetate was administered. Blood was allowed to clot and tubes were centrifuged at 2,500 r.p.m. for 10 min. Serum aliquots were frozen at 280 uC until processing. Drug metabolites and internal standard (d 4 -cortisol, CDN Isotopes) were extracted from 200 ml of patient serum with methyl tert-butyl ether (Sigma Aldrich), evaporated under a stream of nitrogen gas and reconstituted in methanol before mass spectrometry analysis.
Mouse serum collection, derivatization and extraction. At the completion of the mouse xenograft study, mouse serum was collected for steroid analysis. Twenty microlitres of serum and internal standard (d 8 -deoxycorticosterone) was derivatized with hydroxylamine (Sigma Aldrich) 26 . Steroids were extracted with methyl tert-butyl ether (Sigma Aldrich), evaporated under a stream of nitrogen gas and reconstituted in methanol:water (50:50) before mass spectrometry analysis. Stable isotope dilution liquid chromatography-mass spectrometry analysis. Mouse serum analysis. Samples were analysed on a Thermo TSQ Quantiva-Prelude SPLC system (Thermo Scientific) with Aria MX 2.1 and Tracefinder 3.2.368.22 software for instrument controls and quantitation. Analyte separation was achieved with an Accucore 50 mm 3 3 mm, 2.6 mm C18 column (Thermo Scientific) using a mobile phase of liquid chromatography-mass spectrometrygrade methanol and water (Thermo Scientific), a gradient of 25-100% methanol and a flow rate of 0.6 ml min 21 . Steroids were ionized by electrospray ionization and in positive ion mode. Multiple reaction monitoring was used to follow mass
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Extended Data Figure 4 | D4A has a higher affinity for both mutant-type AR (LNCaP cells) and wild-type AR (LAPC4 cells) than abiraterone (Abi) and bicalutamide (Bic) and inhibits AR chromatin occupancy better than Abi. a, Competition plots for D4A, Abi and Bic. b, Competition plots for unlabelled R1881 and D4A. Displacement of [ 3 H]R1881 is described in Methods. Experiments were performed with biological replicates (n 5 3) and results are shown as mean 6 s.d. c, D4A inhibition of AR chromatin occupancy is superior to Abi. LNCaP cells were treated with the indicated concentrations of DHT, D4A, Abi and enzalutamide (Enz) for 3 h. AR chromatin occupancy for PSA, TMPRSS2 and FKBP5 was detected with ChIP. Experiments were performed with technical replicates (n 5 3) and results are shown as mean 6 s.d. All experiments were repeated independently at least three times.
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